DelveInsight’s “Cytokine Release Syndrome Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Cytokine Release Syndrome pipeline landscape. It covers the Cytokine Release Syndrome Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cytokine Release Syndrome Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Cytokine Release Syndrome Pipeline? Click here to explore the therapies and trials making headlines @ Cytokine Release Syndrome Pipeline Outlook Report

Key Takeaways from the Cytokine Release Syndrome Pipeline Report

• On 06 October 2025, Hoffmann-La Roche conducted a study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.
• DelveInsight’s Cytokine Release Syndrome Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Cytokine Release Syndrome treatment.
• The leading Cytokine Release Syndrome Companies such as Biocon Limited, Olatec Therapeutics LLC, Novartis Pharmaceuticals and others.
• Promising Cytokine Release Syndrome Therapies such as CTO1681 10 μg, Itacitinib, Itolizumab IV infusion, Ruxolitinib, Canakinumab, Anakinra and others.

Want to know which companies are leading innovation in Cytokine Release Syndrome? Dive into the full pipeline insights @ Cytokine Release Syndrome Clinical Trials Assessment

The Cytokine Release Syndrome Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Cytokine Release Syndrome Pipeline Report also highlights the unmet needs with respect to the Cytokine Release Syndrome.

Cytokine Release Syndrome Overview

A condition that may occur after treatment with some types of immunotherapy, such as monoclonal antibodies and CAR-T cells. Cytokine release syndrome is caused by a large, rapid release of cytokines into the blood from immune cells affected by the immunotherapy. Cytokines are immune substances that have many different actions in the body.

Cytokine Release Syndrome Emerging Drugs Profile

• Canakinumab: Novartis

Canakinumab is an interleukin (IL)-1β blocker indicated to treat certain periodic fever syndromes, such as cryopyrin-associated periodic syndromes and systemic juvenile idiopathic arthritis. Novartis is conducting phase III trial, called CAN-COVID which will evaluate the drug’s efficacy in treating a type of severe immune overreaction called cytokine release syndrome (CRS) related to Covid-19 pneumonia.

• Itacitinib: Incyte Corporation

Itacitinib is a potent, selective JAK1 inhibitor which is being clinically evaluated in several inflammatory diseases. It is currently being evaluated in phase II stage for the prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy.

• Dapansutrile: Olatec Therapeutics LLC

Dapansutrile is being developed by Olatec Therapeutics LLC for the treatment of Cytokine Release Syndrome. It is currently being evaluated in phase II trial to determine safety and efficacy of Dapansutrile for treatment of moderate COVID-19 symptoms and evidence of Early Cytokine Release Syndrome.

If you’re tracking ongoing Cytokine Release Syndrome Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Cytokine Release Syndrome Treatment Drugs

The Cytokine Release Syndrome Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Cytokine Release Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cytokine Release Syndrome Treatment.
• Cytokine Release Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cytokine Release Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cytokine Release Syndrome market.

Cytokine Release Syndrome Companies

Biocon Limited, Olatec Therapeutics LLC, Novartis Pharmaceuticals and others.

Cytokine Release Syndrome Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Molecule Type

Cytokine Release Syndrome Products have been categorized under various Molecule types such as,

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

From emerging drug candidates to competitive intelligence, the Cytokine Release Syndrome Pipeline Report covers it all – check it out now @ Cytokine Release Syndrome Market Drivers and Barriers, and Future Perspectives

Scope of the Cytokine Release Syndrome Pipeline Report

• Coverage- Global
• Cytokine Release Syndrome Companies- Biocon Limited, Olatec Therapeutics LLC, Novartis Pharmaceuticals and others.
• Cytokine Release Syndrome Therapies such as CTO1681 10 μg, Itacitinib, Itolizumab IV infusion, Ruxolitinib, Canakinumab, Anakinra and others.
• Cytokine Release Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cytokine Release Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Cytokine Release Syndrome Treatment landscape in this detailed analysis @ Cytokine Release Syndrome Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Cytokine Release Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cytokine Release Syndrome – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Cytokine Release Syndrome Collaboration Deals
9. Late Stage Products (Phase III)
10. Canakinumab: Novartis
11. Mid Stage Products (Phase II)
12. Itacitinib: Incyte Corporation
13. Dapansutrile: Olatec Therapeutics LLC
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Pre-clinical and Discovery Stage Products
19. Drug Name: Company Name
20. Inactive Products
21. Cytokine Release Syndrome Key Companies
22. Cytokine Release Syndrome Key Products
23. Cytokine Release Syndrome- Unmet Needs
24. Cytokine Release Syndrome- Market Drivers and Barriers
25. Cytokine Release Syndrome- Future Perspectives and Conclusion
26. Cytokine Release Syndrome Analyst Views
27. Cytokine Release Syndrome Key Companies
28. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cytokine-release-syndrome-pipeline-insight